Pfizer and Genentech Duke it Out in Court over Herceptin Biosimilar Patents Post author:Sam Post published:November 21, 2017 Post category:BioPharma Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Source: BioSpace You Might Also Like CytoSorbents Launches VetResQ For U.S. Veterinary Market January 19, 2017 Amgen Goes on the Defensive When Critics Call Its Pipeline a Dud June 21, 2017 SANUWAVE Announces Shock Wave Scientific Program In Milan, Italy Conducted By 26 May, 2017 May 25, 2017
SANUWAVE Announces Shock Wave Scientific Program In Milan, Italy Conducted By 26 May, 2017 May 25, 2017
